Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies

[1]  Leonard A. Smith,et al.  Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. , 2011, Protein engineering, design & selection : PEDS.

[2]  Leonard A. Smith,et al.  Extraction of BoNT/A, /B, /E, and /F with a Single, High Affinity Monoclonal Antibody for Detection of Botulinum Neurotoxin by Endopep-MS , 2010, PloS one.

[3]  J. Marks,et al.  Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. , 2010, Protein engineering, design & selection : PEDS.

[4]  Y. Seto,et al.  Genetic Characterization of Clostridium botulinum Associated with Type B Infant Botulism in Japan , 2009, Journal of Clinical Microbiology.

[5]  Leonard A. Smith,et al.  Extraction and Inhibition of Enzymatic Activity of Botulinum Neurotoxins/A1, /A2, and /A3 by a Panel of Monoclonal Anti-BoNT/A Antibodies , 2009, PloS one.

[6]  Leonard A. Smith,et al.  The use of Endopep-MS to detect multiple subtypes of botulinum neurotoxins A, B, E, and F , 2008 .

[7]  Leonard A. Smith,et al.  Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. , 2007, Journal of molecular biology.

[8]  L. O. Ticknor,et al.  Genetic Diversity among Botulinum Neurotoxin-Producing Clostridial Strains , 2006, Journal of bacteriology.

[9]  Eric A. Johnson,et al.  SV2 Is the Protein Receptor for Botulinum Neurotoxin A , 2006, Science.

[10]  B. Davletov,et al.  The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves , 2006, FEBS Letters.

[11]  Suzanne R. Kalb,et al.  The use of Endopep-MS for the detection of botulinum toxins A, B, E, and F in serum and stool samples. , 2006, Analytical biochemistry.

[12]  Suzanne R. Kalb,et al.  Botulinum Neurotoxin Detection and Differentiation by Mass Spectrometry , 2005, Emerging infectious diseases.

[13]  R. Siegel,et al.  Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. , 2005, Journal of molecular biology.

[14]  Suzanne R. Kalb,et al.  From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry. , 2005, Analytical chemistry.

[15]  L. Simpson,et al.  Identification of the major steps in botulinum toxin action. , 2004, Annual review of pharmacology and toxicology.

[16]  J. Marks,et al.  Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin. , 2001, Toxicon : official journal of the International Society on Toxinology.

[17]  Philip K. Russell,et al.  Botulinum toxin as a biological weapon: medical and public health management. , 2001, JAMA.

[18]  J. Marks,et al.  Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries , 1997, Infection and immunity.

[19]  R. Stevens,et al.  Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms , 1997, Infection and immunity.

[20]  G. Pugliese,et al.  Severe Streptococcus pyogenes Infections, United Kingdom, 2003–2004 , 2008, Emerging infectious diseases.

[21]  R. Stevens,et al.  Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin , 2007, Nature Biotechnology.